the number of litres per day of oil flowing from the ruptured Gulf of Mexico well, up to four times the official estimate from a month ago. • EVEnts Top kill fails: BP's latest efforts to staunch the flow of oil from its wellhead in the Gulf of Mexico have failed, prompting White House energy adviser Carol Browner to admit that the leak may not be stopped before August, when drilling for relief wells will be completed. The 'top kill' operation -pumping mud into the gushing wellwas followed by a 'junk shot' to block the oil leak with debris. Neither attempt worked. Robot submarines are now being deployed to cap the well. See page 532 for more.
the Free State in Bloemfontein found that the new variants can overcome the effects of two resistance genes in wheat that normally prevent stem rust from taking hold. There is concern that winds will help the fungus to migrate further, threatening crops in areas including the Middle East and south Asia. See go.nature.com/flSdmx for more.
Pharmaceutical and biotech companies are outsourcing ever more stages of the drug-discovery process. Much of that growth will be in emerging markets, as companies take advantage of the low costs and deep talent pools in countries such as India and China. The 300 US-based CROs still generate about half of the industry's revenue, and are predicted to grow each year by 14%. But in China, where drug development is about 20% of the cost in the United States and western europe, the industry is expected to swell by 33% each year, reaching $791 million by 2012. Meanwhile, the proportion of global clinical trials conducted in India will grow from 2% in 2007 to 5% in 2012. These trends have been highlighted by leading US CROs such as Quintiles in Durham, North Carolina, and Charles River laboratories in Wilmington, Massachusetts, shifting more of their operations to emerging markets.
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